<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35690233</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-1208</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Microbial pathogenesis</Title><ISOAbbreviation>Microb Pathog</ISOAbbreviation></Journal><ArticleTitle>Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran.</ArticleTitle><Pagination><StartPage>105618</StartPage><MedlinePgn>105618</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.micpath.2022.105618</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0882-4010(22)00231-5</ELocationID><Abstract><AbstractText>The prevalence and variety complaints of COVID-19 cases in a long term have been investigated in recent studies. The symptoms over the time are various and unpredictable which may persist several weeks after full recovery. The importance of long-COVID-19 manifestations includes its effect on the recovered cases which requires a rational management based on an accurate guideline to handle post-acute COVID-19 state. The aim of this study was to evaluate the incidence of post-acute COVID-19 syndrome and to identify the associated risk factors as well as to compare new and persistent symptoms at different post-acute phases. Totally 254 individuals from Pasteur Institute of Iran (or/and their relatives) were investigated who had a previously confirmed COVID-19 PCR test. The long-term manifestations of the virus were categorized through a time window as acute, ongoing, post-COVID and persistent phases and the individuals were assessed by the face-to-face or the phone call interview according to their complaints. The data were then statistically analyzed to determine the frequency of the symptoms and also the associated factors in which a p value&#xa0;&lt;&#xa0;0.05 was considered significant. Except a small asymptotic group of five, 249 cases progressed the symptoms to acute phase among which 64.1% reported at least one symptom in post-acute phase. Neurological sequelae were found as the most frequent symptom (91.6%). Furthermore, there was a significant association between the underlying diseases, age and acute phase symptoms to the post-acute phase syndrome susceptibility (p&#xa0;&lt;&#xa0;0.05). In conclusion, the increasing number of the reports and studies on long COVID-19 which can hugely affect the life quality should be more investigated and explored in terms of the pathophysiology to achieve appropriate treatments in time. The clusters of symptoms, specially a combination of neurological signs, presenting over months after the recovery impose a huge difficulty to the recovered population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadat Larijani</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran. Electronic address: mona.sadat@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashrafian</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran. Electronic address: fatemeh.ashrafian24@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagheri Amiri</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran. Electronic address: drop.dr.bagheri@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banifazl</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran. Electronic address: mohammadbanifazl@aol.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bavand</LastName><ForeName>Anahita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran. Electronic address: anahita.bavand@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karami</LastName><ForeName>Afsaneh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Zanjan University of Medical Sciences, Zanjan, Iran. Electronic address: dr.akarami@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asgari Shokooh</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran. Electronic address: shokooh.f4973@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramezani</LastName><ForeName>Amitis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Dept., Pasteur Institute of Iran, Tehran, Iran. Electronic address: amitisramezani@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Microb Pathog</MedlineTA><NlmUniqueID>8606191</NlmUniqueID><ISSNLinking>0882-4010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic</Keyword><Keyword MajorTopicYN="N">Iran</Keyword><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">Manifestation</Keyword><Keyword MajorTopicYN="N">Persistent SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Post-acute</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35690233</ArticleId><ArticleId IdType="pmc">PMC9176176</ArticleId><ArticleId IdType="doi">10.1016/j.micpath.2022.105618</ArticleId><ArticleId IdType="pii">S0882-4010(22)00231-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salehi-Vaziri M., Omrani M.D., Pouriayevali M.H., Fotouhi F., Banifazl M., Farahmand B., et al. SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses. Virus Res. 2021;299</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022517</ArticleId><ArticleId IdType="pubmed">33836204</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi-Vaziri M., Pouriayevali M.H., Fotouhi F., Jalali T., Banifazl M., Farahmand B., et al. SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microb. Pathog. 2021;161</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8599135</ArticleId><ArticleId IdType="pubmed">34801646</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotouhi F., Salehi-Vaziri M., Farahmand B., Mostafavi E., Pouriayevali M.H., Jalali T., et al. Prolonged viral shedding and antibody persistence in patients with COVID-19. Microb. Infect. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963517</ArticleId><ArticleId IdType="pubmed">33741515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa Salehi-Vaziri T.J., Farahmand Behrokh, Fotouhi Fatemeh, Banifazl Mohammad, Hassan Pouriayevali Mohammad, Sadat Larijani Mona, Neda Afzali, Ramezani Amitis. European Journal of Clinical Microbiology &amp; Infectious Diseases; 2021. Clinical Characteristics of SARS-CoV-2 by Re-infection vs. Reactivation: A Case Series from Iran.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972329</ArticleId><ArticleId IdType="pubmed">33738620</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi-Vaziri M., Jalali T., Farahmand B., Fotouhi F., Banifazl M., Pouriayevali M.H., et al. Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(8):1713&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972329</ArticleId><ArticleId IdType="pubmed">33738620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofian M., Velayati A.A., Banifazl M., Fotouhi F., Sadat Larijani M., Afzali N., et al. SARS-CoV-2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms. Wien Med. Wochenschr. 2021;171(1):3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734614</ArticleId><ArticleId IdType="pubmed">33315163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau H.M., Lee E.W., Wong C.N., Ng G.Y., Jones A.Y., Hui D.S. The impact of severe acute respiratory syndrome on the physical profile and quality of life. Arch. Phys. Med. Rehabil. 2005;86(6):1134&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094462</ArticleId><ArticleId IdType="pubmed">15954051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.M., Wong J.G., McAlonan G.M., Cheung V., Cheung C., Sham P.C., et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Canadian J. psych Revue canadienne de psychiatrie. 2007;52(4):233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17500304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam M.H., Wing Y.K., Yu M.W., Leung C.M., Ma R.C., Kong A.P., et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch. Intern. Med. 2009;169(22):2142&#x2013;2147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>van Loenhout J.A., van Tiel H.H., van den Heuvel J., Vercoulen J.H., Bor H., van der Velden K., et al. Serious long-term health consequences of Q-fever and Legionnaires' disease. J. Infect. 2014;68(6):527&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">24468188</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjana N.K.N., Annie T.T., Siba S., Meenu M.S., Chintha S., Anish T.S.N. Manifestations and risk factors of post COVID syndrome among COVID-19 patients presented with minimal symptoms &#x2013; a study from Kerala, India. J. Fam. Med. Prim. Care. 2021;10(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8797119</ArticleId><ArticleId IdType="pubmed">35136762</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a L.F. Immune response, inflammation, and the clinical spectrum of COVID-19. Front. Immunol. 2020;11(1441)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308593</ArticleId><ArticleId IdType="pubmed">32612615</ArticleId></ArticleIdList></Reference><Reference><Citation>Glans H., Gredmark-Russ S., Olausson M., Falck-Jones S., Varnaite R., Christ W., et al. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses. BMC Infect. Dis. 2021;21(1):494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159068</ArticleId><ArticleId IdType="pubmed">34044758</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int. Urol. Nephrol. 2020;52(6):1193&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103107</ArticleId><ArticleId IdType="pubmed">32222883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Wang Y., Shao C., Huang J., Gan J., Huang X., et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091918</ArticleId><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusano G., Pastori C., Lopalco L. Humoral immune responses in COVID-19 patients: a window on the state of the art. Front. Immunol. 2020;11(1049)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242756</ArticleId><ArticleId IdType="pubmed">32574261</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam. Pract. 2022;39(1):159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vera-Lastra O., Lucas-Hern&#xe1;ndez A., Ruiz-Montiel J.E., Gonzalez-Rodriguez V.R., Pineda-Galindo L.F. Myopericarditis as a manifestation of long COVID syndrome. Cureus. 2021;13(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8664614</ArticleId><ArticleId IdType="pubmed">34912599</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer R.R., Rock M.A., Vasilevsky N., Carmody L., Rando H., Anzalone A.J., et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M., Brito-Zer&#xf3;n P., Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat. Rev. Rheumatol. 2021;17(6):315&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez O.M., Bridges N.D., Goldmuntz E., Pascual V. The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. Nat. Med. 2020;26(12):1819&#x2013;1824.</Citation><ArticleIdList><ArticleId IdType="pubmed">33139949</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L.R., Rose E.B., Horwitz S.M., Collins J.P., Newhams M.M., Son M.B.F., et al. Multisystem inflammatory syndrome in U.S. Children and adolescents. N. Engl. J. Med. 2020;383(4):334&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman K.G., Gauvreau K., Hamaoka-Okamoto A., Tang A., Berry E., Tremoulet A.H., et al. Coronary artery aneurysms in kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population. J. Am. Heart Assoc. 2016;5(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079009</ArticleId><ArticleId IdType="pubmed">27633390</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez S.R., Friedman K., Seewald R., Anderson M.S., Willis L., Glod&#xe9; M.P. Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics. 2008;122(4):e786&#x2013;e790.</Citation><ArticleIdList><ArticleId IdType="pubmed">18809597</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Chang I.S., Lu C.Y., Chiang B.L., Lee C.Y., Chen P.J., et al. Epidemiologic features of kawasaki disease in Taiwan, 1996-2002. Pediatrics. 2004;114(6):e678&#x2013;e682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15574600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma C., Ganigara M., Galeotti C., Burns J., Berganza F.M., Hayes D.A., et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat. Rev. Rheumatol. 2021;17(12):731&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554518</ArticleId><ArticleId IdType="pubmed">34716418</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re'em Y., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical trials [internet]. U.S National library of medicine [cited april 15, 2020] https://clinicaltrials.gov/ Available from:</Citation></Reference><Reference><Citation>Sonnweber T., Sahanic S., Pizzini A., Luger A., Schwabl C., Sonnweber B., et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur. Respir. J. 2021;57(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736754</ArticleId><ArticleId IdType="pubmed">33303539</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerahandi H., Hochman K.A., Simon E., Blaum C., Chodosh J., Duan E., et al. Post-discharge health status and symptoms in patients with severe COVID-19. J. Gen. Intern. Med. 2021;36(3):738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808113</ArticleId><ArticleId IdType="pubmed">33443703</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackett J.W., Li J., Jodorkovsky D., Freedberg D.E. Prevalence and risk factors for gastrointestinal symptoms after recovery from COVID-19. Neuro Gastroenterol. Motil. : Eur. J. Gastrointest. Motil. Soc. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646904</ArticleId><ArticleId IdType="pubmed">34468069</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain N., Agarwala P., Iqbal K., Omar H.M.S., Jangid G., Patel V., et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J. Med. Virol. 2022;94(4):1391&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">34931698</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., Palese A., Venturini M., De Martino M., Gerussi V., Graziano E., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2021;27(10):1507&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya A.A., Akbari A., Emami A., Lotfi M., Rostamihosseinkhani M., Nemati H., et al. Risk factors associated with long COVID syndrome: a retrospective study. Iran. J. Med. Sci. 2021;46(6):428&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeloye D., Elneima O., Daines L., Poinasamy K., Quint J.K., Walker S., et al. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir. Med. 2021;9(12):1467&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8372501</ArticleId><ArticleId IdType="pubmed">34416191</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley R., Kearns N., Hills T. Charting a course for the management of long COVID. Lancet Respir. Med. 2021 Dec 1;9(12):1358&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8372495</ArticleId><ArticleId IdType="pubmed">34416190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>